Advanced Search
Article Contents
ABOUT THIS ARTICLE
The Innovation Medicine > 2026 Vol. 4 > No. 1 > 100181
Next Article Previous Article
COMMENTARY   Open Access     Cite

C5aR inhibitors: New dawn and challenges from pathophysiological mechanisms to clinical treatment

  • 1.

    Biomedical Innovation Center, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China

  • 2.

    Beijing Key Laboratory for Therapeutic Cancer Vaccines, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China

  • 3.

    Department of Pharmacy, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China

More Information
The Innovation Medicine  4(1),  https://doi.org/10.59717/j.xinn-med.2026.100181  |  Cite this article
    • FullText(HTML)
  • 加载中
    • REFERENCES
  • [1] Jayne D.R.W., Merkel P.A., Schall T.J., et al. (2021). Avacopan for the treatment of ANCA-associated vasculitis. N. Engl. J. Med. 384:599−609. DOI:10.1056/NEJMoa2023386

    View in Article CrossRef Google Scholar

    [2] Fouka E., Drakopanagiotakis F. and Steiropoulos P. (2024). Pathogenesis of pulmonary manifestations in ANCA-associated vasculitis and goodpasture syndrome. Int. J. Mol. Sci. 25:5278. DOI:10.3390/ijms25105278

    View in Article CrossRef Google Scholar

    [3] Krysko K.M., Dobson R., Alroughani R., et al. (2023). Family planning considerations in people with multiple sclerosis. Lancet Neurol. 22:350−366. DOI:10.1016/s1474-4422(22)00426-4

    View in Article CrossRef Google Scholar

    [4] Vlaar A.P.J., Witzenrath M., van Paassen P., et al. (2022). Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): A multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Respir. Med. 10:1137−1146. DOI:10.1016/s2213-2600(22)00297-1

    View in Article CrossRef Google Scholar

    [5] Jucker M. and Walker L.C. (2023). Alzheimer's disease: From immunotherapy to immunoprevention. Cell 186:4260−4270. DOI:10.1016/j.cell.2023.08.021

    View in Article CrossRef Google Scholar

    • Cited by

  • Cite this article:

    Gao Y. and Yan J. (2026). C5aR inhibitors: New dawn and challenges from pathophysiological mechanisms to clinical treatment. The Innovation Medicine 4:100181. https://doi.org/10.59717/j.xinn-med.2026.100181
    Gao Y. and Yan J. (2026). C5aR inhibitors: New dawn and challenges from pathophysiological mechanisms to clinical treatment. The Innovation Medicine 4:100181. https://doi.org/10.59717/j.xinn-med.2026.100181

Welcome!

To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.

PDF
Figures(1)    

Share

  • Share the QR code with wechat scanning code to friends and circle of friends.

Article Metrics

Article views(3851) PDF downloads(2023)

Relative Articles

Cited by

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return

    {{newsColumn.name}}

    {{newsColumn.name}}

    Stay connected

    {{newsColumn.name}}

    Website copyright © Innovation Press. Published articles are licensed under CC BY with copyright retained by the authors.